Butanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)- | 106983-29-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Butanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-
• 英文别名: 3-oxo-N-(2-oxooxolan-3-yl)butanamide
• CAS: 106983-29-3
• 化学式: C₈H₁₁NO₄
• 分子量: 185.18
• InChiKey: FIHPLICEAUNEFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  72.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• N-((S)-2-Oxo-tetrahydro-furan-3-yl)-amide derivatives as inhibitors of the bacterial quorum sensing for treating plant or animal diseases and for preventing the formation of biofilms on medical devices
  申请人：The National Institute for Biotechnology in the Negev Ltd.

  公开号：EP2448930B1

  公开（公告）日：2017-02-15
• Methods For The Treatment Of An Infectious Bacterial Disease With An Anti-Lactone Or Lactone Derived Signal Molecules Antibody
  申请人：Charlton Keith Alan

  公开号：US20100303831A1

  公开（公告）日：2010-12-02

  The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant.
• NOVEL ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE
  申请人：The Trustees of Princeton University

  公开号：US20190307818A1

  公开（公告）日：2019-10-10

  The invention relates to compositions for inhibiting or agonizing quorum sensing (QS) pathways to repress biofilm formation, biofilm streamer formation, virulence factor production, and/or infections (including bacterial infections and bacterial infections with resistance to antibiotics) by: (a) a monotherapy using novel compounds, such as small molecule inhibitors or agonists, to inhibit or activate QS activation pathways and/or (b) a combination therapy including novel compounds to inhibit or activate QS and/or to sensitize bacteria to phage along with phage therapy. These compositions can be used to treat patients having infections. Additionally, these compositions can be used to treat surfaces/areas known to contain human pathogens notorious for causing hospital-acquired infections (such as intravenous catheters, implants, medical devices) as well as fatal infections that occur outside of health care settings. Preferred microorganisms that can be treated with the compositions of the invention include, but are not limited to bacterial strains resistant to one or more antibiotics.
• US7812134B2
  申请人：——

  公开号：US7812134B2

  公开（公告）日：2010-10-12
• US8168397B2
  申请人：——

  公开号：US8168397B2

  公开（公告）日：2012-05-01